Manufacturer’s dossier did not contain suitable data for any therapeutic indication Dapagliflozin (trade name: Forxiga) has been approved in Germany since November 2012 for the treatment of type 2 diabetes mellitus. In an early benefit assessment pursuant to the Act… Read More ›
Combination therapy
Chronic hepatitis C: Interferon may be harmful in re-treatment: “may face an increased risk of dying sooner”
Contact: Jennifer Beal sciencenewsroom@wiley.com 44-012-437-70633 Wiley People with hepatitis C and chronic liver disease who relapsed or failed to respond to initial treatment are unlikely to improve on interferon retreatment. In fact, they may face an increased risk of dying… Read More ›
Engineering Evil 